Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
and used in cancer research
N106 treatment increases contractile properties of cultured rat cardiomyocytes and significantly improves ventricular function in mice with heart failure
The unfolded protein response signals through high-order assembly of Ire1
It is a synthetic derivative of all-trans-retinoic acid developed through the structure-based chemical design
PHF8 at IC50 ~0
ABT-199 - BCL-2 inhibitor. CAS# 1257044-40-8 Catalog No.:M60075-10S and used in cancer researchABT 199, CAS No. 1257044 40 8, is a highly potent, selective, and orally bioavailable BCL 2 inhibitor. ABT 199 has picomolar affinity for BCL 2 (Ki < 0. 010 nM) and > 1000 folds selectivity over BCL XL (Ki = 48 nM) and BCL W (Ki = 245 nM). Therefore, ABT 199 is a much improved lead compound over the original ABT 263 (navitoclax) to avoid thrombocytopenia caused by BCL XL inhibition. ABT 199s cell killing effect is selective and mechanism dependent. It
US$ 3920.00
US$ 1087.50
US$ 1790.00
US$ 34.00
US$ 100.00
US$ 49.95
US$ 1000.00
US$ 130.00
US$ 130.00
US$ 3400.00
US$ 2205.00
US$ 1685.00